Guru P. Sonpavde, MD
@sonpavde
Phase I+GU Oncology Director @AdventHealthCFL #Cancer Institute, Prof. @ucf Orlando, #Florida, #ASCO, #ESMO, #AACR, Following/Retweet โ endorsement, Views mine
ID: 2437680197
https://www.adventhealthcancerinstitute.com/ 26-03-2014 11:12:03
1,1K Tweet
4,4K Followers
210 Following
#GU25: Key #bladdercancer presentations (in my opinion)- highlights and summary coming after the conference from AdventHealth Central Florida #cancer Institute- please note OncoAlert LARVOL OncLive.com GU Oncology Now SWOG Cancer Research Network Research To Practice PeerView Doximity
#GU25 #bladdercancer commentary: PD1/L1 Inhibitor Therapy for Muscle-Invasive Bladder Cancer: Adjuvant or Neoadjuvant + Adjuvant?" Pleased to comment from AdventHealth Central Florida #cancer Institute- OncoAlert Yรผksel รrรผn Enrique Grande Shilpa Gupta Andrea Necchi Matt Galsky
๐บ A virtual roundtable hosted by Petros Grivas contextualized the latest #bladdercancer research updates and trials of relevancy to come out of ASCO #GU25, with panelists Guru P. Sonpavde, MD, Elizabeth Plimack MD, Christopher Wallis (he/him/his), Terry Friedlander, and Matt Galsky: buff.ly/jz0gBrc ๐ In part
โญ๏ธ Loved this tough case presentation below by Dr. Priyanka Chablani. Priyanka Chablani, MD, MS Great discussion with Guru P. Sonpavde, MD Matt Milowsky Petros Grivas #ZachSnowMD UroToday.com ONCO BRUNO MedNewsWeek OncoAlert OncoDaily The Medical Educator Consortium
#AACR25 #clinicaltrial highlights - looking forward to highlighting from AdventHealth Central Florida #cancer Institute UCF College of Medicine
WATCH: Guru P. Sonpavde, MD of AdventHealth Central Florida discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC. Watch more here: hubs.li/Q03dXmWk0
#AACR25 AACR pleased to preview #clinicaltrial highlights of developmental therapeutics across solid tumors - and #bladdercancer #ProstateCancer #kidneycancer - from AdventHealth Central Florida AdventHealth
#bladdercancer systemic #immunotherapy biomarker paper in Journal for ImmunoTherapy of Cancer Society for Immunotherapy of Cancer: Pre-emptive identification of patients at high risk of primary refractory disease on any systemic therapy is challenging but necessary to enable an early switch to other treatment choices before
Honored to participate from AdventHealth Central Florida #cancer Institute, Orlando, #Florida and Dana-Farber News Dana-Farber Lank Center for Genitourinary Oncology
Ab#4500 ASCO #ASCO25 by Michiel van der Heijden๐bit.ly/4kwoaic๐IPI+NIVO vs Gem+Carbo in ph 3 CheckMate 901 trial in cis-ineligible 1L mUC #bladdercancer๐NIVO+IPI did not improve OS๐Guru P. Sonpavde, MD Matt Galsky Tom Powles UroToday.com Bladder Cancer Advocacy Network
#bladdercancer perioperative therapy - pleased to comment in European Urology Focus - Perioperative durvalumab (ie not just neoadjuvant) combined with neoadjuvant cisplatin-based chemotherapy should be the current preferred strategy for most patients with muscle-invasive disease
Always a pleasure to speak with Guru P. Sonpavde, MD of AdventHealth and our conversation at #ASCO25 was no different! Hear Dr Sonpavde preview his interview on results of the CheckMate 901 trial in cisplatin-ineligible mUC below! ASCO #blcsm
Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer Guru P. Sonpavde, MD AdventHealth ASCO #ASCO25 #MedTwitter curetoday.com/view/breaking-โฆ
#ASCO25 GU #cancer highlights- pleased to comment in Doximity from AdventHealth Central Florida AdventHealth Yรผksel รrรผn Enrique Grande Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Shilpa Gupta doximity.com/newsfeed/85023โฆ